Fatma Moawad

Mrs. Fatma Moawad

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2024 in Small
Verified
Journal Article
Open access
FMFatma Moawad
Fatma Moawad
YRYasmine Ruel
Yasmine Ruel
NRNastaran Rezaei
Nastaran Rezaei
JAJérôme Alsarraf
Jérôme Alsarraf
APAndré Pichette
André Pichette
DBDavide Brambilla
Davide Brambilla
Methotrexate is successfully used as the gold standard for managing moderate‐to‐severe psoriasis. However, the low bioavailability and short half‐life of the oral pills and the invasiveness of the parenteral injections make these suboptimal therapeutic options. Microneedles, bridging the advantages of the former forms, are successfully used to deliver methotrexate for different therapeutic purposes. However, the utilized dissolving microneedles demand frequent administration, potentially compromising patients’ compliance. Additionally, the high toxicity of methotrexate prompts a quest for safer alternatives. Phloretin, a natural compound with confirmed antipsoriatic potential, emerges as a promising candidate. Herein, microneedle patches with separable, slow‐degrading tips are developed for the sustained delivery of methotrexate and phloretin, as a comprehensive solution for long‐term psoriasis management. Both compounds are individually loaded at varying doses and display sustained‐release profiles. The developed microneedle patches demonstrate high mechanical strength, favorable drug delivery efficiency, and remarkable antipsoriatic potential both in vitro in keratinocytes and in vivo in a psoriasis mouse model. Comparative analysis with two subcutaneous injections reveals a similar antipsoriatic efficacy with a single patch of either compound, with prominent phloretin safety. Therefore, the developed patches present a superior alternative to methotrexate's current marketed forms and provide a viable alternative (phloretin) with comparable antipsoriatic efficacy and higher safety.

Verified
Journal Article
Open access
PDF file
YRYasmine Ruel
Yasmine Ruel
FMFatma Moawad
Fatma Moawad
JAJérôme Alsarraf
Jérôme Alsarraf
APAndré Pichette
André Pichette
JLJean Legault
Jean Legault
Roxane PouliotRoxane Pouliot
Roxane Pouliot
Plaque psoriasis is a chronic inflammatory skin disease causing red inflamed lesions covered by scales. Leukocytes, including dendritic cells and T cells, participate in the inflammation of the skin by producing multiple cytokines, thus contributing to the hyperproliferation of keratinocytes. Lack of effectiveness and toxic side effects are the main concerns with conventional treatments, and research involving new antipsoriatic molecules is essential. In this study, the anti-inflammatory and antiproliferative effects of two natural polyphenols, phloretin and balsacone C, were investigated using the coculture of T cells and psoriatic keratinocytes. Phloretin exerted antiproliferative activity by regulating the expression of antigen Ki67 and proliferating cell nuclear antigen (PCNA). These effects were comparable to those of methotrexate, a reference treatment for moderate to severe psoriasis. With balsacone C, the expression of Ki67 was also reduced. Additionally, phloretin decreased the levels of multiple pro-inflammatory cytokines: monocyte chemoattractant protein-1 (MCP-1/CCL2), macrophage inflammatory protein-1α (MIP-1α), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-17A (IL-17A), and tumor necrosis factor alpha (TNF-α). The increased interleukin-2 (IL-2) levels with phloretin and methotrexate also represented anti-inflammatory activity. Balsacone C and methotrexate decreased the levels of IL-1α and IL-1β, but methotrexate exerted a higher reduction. In summary, the anti-inflammatory effects of phloretin were more pronounced than those of methotrexate and balsacone C. In addition, the expression of lymphocyte common antigen (CD45) was more similar to that of the healthy condition after using phloretin or methotrexate. Finally, phloretin stood out from the other compounds and appears promising for psoriasis treatment.

3 December 2025 in Advanced Healthcare Materials
Verified
Journal Article
Open access
FMFatma Moawad
Fatma Moawad
YRYasmine Ruel
Yasmine Ruel
RPRoxane Pouliot
Roxane Pouliot
DBDavide Brambilla
Davide Brambilla
Psoriasis is a chronic dermatological disorder that affects millions worldwide, impairing their quality of life. Current therapeutic modalities, topical, conventional systemic, and biologic, present significant limitations. Topical agents often exhibit inadequate penetration through psoriatic plaques, yielding suboptimal outcomes. Systemic therapies and biologics, while more potent, carry risks of serious adverse effects, necessitating rigorous monitoring and limiting their long‐term utility. Despite these challenges, optimizing existing treatment strategies remains valuable. Microneedle technology has emerged as a minimally invasive, skin‐targeted approach offering enhanced drug delivery, localization, and patient compliance. This review provides an in‐depth analysis of microneedle‐based strategies tailored for psoriasis, beginning with current therapy shortcomings, unmet needs in psoriasis management, and principles of microneedle technology. We then critically evaluate microneedle integration across diverse therapeutic domains, from topical formulations to biologics, off‐label therapies, and phytomedicines, alongside emerging therapeutic innovations. Additionally, we highlight microneedle potential in psoriasis diagnosis and monitoring, underscoring its versatility and growing significance in psoriasis management. The review wraps up by discussing key limitations of microneedle technology, outlining strategic pathways for clinical translation, and offering a comparative perspective of various microneedle types in psoriasis care. Altogether, microneedles represent a paradigm shift toward precision dermatology, with the potential to revolutionize psoriasis management.

4 August 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NTNolwenn Tessier
Nolwenn Tessier
FMFatma Moawad
Fatma Moawad
NANada Amri
Nada Amri
DBDavide Brambilla
Davide Brambilla
CMCatherine Martel
Catherine Martel
While oral agents have been the gold standard for cardiovascular disease therapy, the new generation of treatments is switching to other administration options that offer reduced dosing frequency and more efficacy. The lymphatic network is a unidirectional and low-pressure vascular system that is responsible for the absorption of interstitial fluids, molecules, and cells from the peripheral tissue, including the skin and the intestines. Targeting the lymphatic route for drug delivery employing traditional or new technologies and drug formulations is exponentially gaining attention in the quest to avoid the hepatic first-pass effect. The present review will give an overview of the current knowledge on the involvement of the lymphatic vessels in drug delivery in the context of cardiovascular disease.

2 September 2025 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
YRYasmine Ruel
Yasmine Ruel
FMFatma Moawad
Fatma Moawad
EJEmmy Jean
Emmy Jean
CNCatherine Nadeau
Catherine Nadeau
JAJérôme Alsarraf
Jérôme Alsarraf
Roxane PouliotRoxane Pouliot
Roxane Pouliot

4 December 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
FMFatma Moawad
Fatma Moawad
MMMarion Le Meur
Marion Le Meur
YRYasmine Ruel
Yasmine Ruel
VRValérie Gaëlle Roullin
Valérie Gaëlle Roullin
Roxane PouliotRoxane Pouliot
Roxane Pouliot
DBDavide Brambilla
Davide Brambilla